Clinical Efficacy and Safety Evaluation of TNF-<i>α</i> Antagonist Ultrasound-Guided Knee Injection for Rheumatoid Arthritis

Objective: To explore the efficacy and safety of knee joint injection of TNF-α antagonist (Yisaipu injection) in patients with rheumatoid arthritis under ultrasound “visualization” guidance. Methods: A total of 240 patients with rheumatoid arthritis from Jingzhou First People’s Hospital were selected as research subjects between May 2024 and May 2025, randomly divided into a control group (120 patients) and an intra-articular injection group (120 patients). The control group received treatment with prednisone tablets 10mg qd + methotrexate 10mg qw; the intra-articular injection group received an additional 25mg TNF-α antagonist (Yisaipu injection) via knee joint puncture under ultrasound guidance. Data on knee joint MSUS ultrasound scores, erythrocyte sedimentation rate, C-reactive protein, and DAS28 score were collected at 0, 3, and 6 months post-treatment for observation of therapeutic effects. Results: After treatment, the knee joint MSUS ultrasound scores, serological indicators, and DAS28 scores in the intra-articular injection group showed significant improvement compared to the control group, with no significant adverse reactions observed. Conclusion: Under ultrasound “visualization” guidance, knee joint injection of TNF-α antagonist in patients with rheumatoid arthritis has significant efficacy and high safety, and musculoskeletal ultrasound assessment can provide effective evidence.